Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions, set ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

SGLT2 diabetes meds like Jardiance or Farxiga do the same, and also decrease risk of a follow-up stroke MONDAY, Nov. 11, 2024 ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...

SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity ...

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

Of note, a similar proportion of patients in the empagliflozin and placebo groups (43% and 40%, respectively) were using an SGLT2 inhibitor during the post-trial period, they wrote in the New ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent ...